ATE449787T1 - Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden - Google Patents

Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden

Info

Publication number
ATE449787T1
ATE449787T1 AT99970091T AT99970091T ATE449787T1 AT E449787 T1 ATE449787 T1 AT E449787T1 AT 99970091 T AT99970091 T AT 99970091T AT 99970091 T AT99970091 T AT 99970091T AT E449787 T1 ATE449787 T1 AT E449787T1
Authority
AT
Austria
Prior art keywords
present
mage
ctl clones
isolated
ctl
Prior art date
Application number
AT99970091T
Other languages
English (en)
Inventor
Pascal Chaux
Rosalie Luiten
Nathalie Demotte
Marie-Therese Duffour
Christophe Lurquin
Catia Traversari
Vincent Stroobant
Guy Cornelis
Thierry Boon-Falleur
Der Bruggen Pierre Van
Erwin Schultz
Guy Warnier
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority claimed from PCT/IB1999/001664 external-priority patent/WO2000020445A2/en
Application granted granted Critical
Publication of ATE449787T1 publication Critical patent/ATE449787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99970091T 1998-10-02 1999-09-15 Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden ATE449787T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/165,863 US6407063B1 (en) 1998-10-02 1998-10-02 Tumor antigens and CTL clones isolated by a novel procedure
US09/289,350 US6531451B1 (en) 1998-10-02 1999-04-09 Tumor antigens and CTL clones isolated by a novel procedure
PCT/IB1999/001664 WO2000020445A2 (en) 1998-10-02 1999-09-15 Tumor antigens and ctl clones isolated by a novel procedure

Publications (1)

Publication Number Publication Date
ATE449787T1 true ATE449787T1 (de) 2009-12-15

Family

ID=22600796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970091T ATE449787T1 (de) 1998-10-02 1999-09-15 Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden

Country Status (4)

Country Link
US (2) US6407063B1 (de)
JP (1) JP4722289B2 (de)
AT (1) ATE449787T1 (de)
DE (1) DE69941719D1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7786278B2 (en) * 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
CA2547635C (en) 2003-12-12 2016-02-09 Jeffrey Schlom A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP1761662A4 (de) * 2004-07-01 2010-02-03 Univ California Proteomik mit hohem durchsatz
CN101041816B (zh) * 2006-12-01 2010-08-25 扬州大学 人工抗原递呈细胞及其制备方法
ES2845203T3 (es) 2008-07-01 2021-07-26 Genocea Biosciences Inc Sistema de análisis de antígenos
CN109476724B (zh) * 2016-04-08 2023-04-04 艾达普特免疫有限公司 T细胞受体
US10859566B2 (en) 2017-03-20 2020-12-08 Genocea Biosciences, Inc. Treatment methods
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
MX2021010831A (es) 2019-03-08 2021-12-15 Obsidian Therapeutics Inc Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
AU2020290522A1 (en) 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
CN111534546A (zh) * 2020-05-09 2020-08-14 赛诺（深圳）生物医药研究有限公司 一种具有多等位基因p53编码序列的重组腺病毒的制备方法
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0656788B1 (de) * 1992-08-07 2006-10-18 Pharmexa Inc. Hla bindepeptide und ihre verwendungen
US5558995A (en) 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US6328971B1 (en) 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
PT879282E (pt) * 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses

Also Published As

Publication number Publication date
US6531451B1 (en) 2003-03-11
JP2003518911A (ja) 2003-06-17
JP4722289B2 (ja) 2011-07-13
DE69941719D1 (de) 2010-01-07
US6407063B1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
ATE449787T1 (de) Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
WO2000020445A3 (en) Tumor antigens and ctl clones isolated by a novel procedure
ES2924709T3 (es) Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
US10968430B2 (en) Use of specific regulatory T-cells to induce immune tolerance
Kimura et al. cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2 (+) cytotoxic T lymphocytes
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
HRP20220131T1 (hr) Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste
DK0512112T3 (da) Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier
AR018064A1 (es) Proteina de fusion que consiste en un antigeno asociado a tumores derivado de la familia mage, secuencia de acido nucleico que la codifica, vector que lo comprende, celula huesped que no puede generar un individuo completo transformada con dicho acido nucleico, vacuna que contiene dicha proteina, su
EP4253958A3 (de) Mittel und verfahren zur glykoprofilierung eines proteins
BR9809656A (pt) Composição imunopotencializante
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
CN112639136A (zh) 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
Golstein et al. Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions
DK0570489T3 (da) Leverstadium-specifikke peptidsekvenser af P.falciparum, der bærer epitoper, som er i stand til at stimulere T-lymfocytter
Rettman et al. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors
Bergman et al. Characterization of H+, K+‐ATPase T cell epitopes in human autoimmune gastritis
DE602006010934D1 (de) Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
Kimura et al. Cytotoxic T lymphocyte membrane components: an analysis of structures related to function
Levin et al. Potent activation of human T cells by mRNA encoding constitutively active CD40
TW200611706A (en) Cytotoxic t lymphocyte
RU2005106841A (ru) Эпитопы т-клеток в эритропоэтине
DE69833455D1 (de) Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1117679

Country of ref document: EP